NCT04598893
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 16 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 2 words Show 4 more changesShow less
- Trial completed
- Primary and study completion dates changed from estimate of Nov 2026 to Nov 12, 2026
- Secondary endpoints: details revised at 1 of 3 entries
- Site details revised at 19 of 47 sites
- Minor Site details revised at 3 of 47 sitesv17
- Notable Lead sponsor: Provention Bio, Inc. to Provention Bio, a Sanofi Companyv16
- Notable Primary endpoint revised
- Secondary endpoints revised (3)
Notable Eligibility criteria revisedv14 Show 5 more changesShow less
- Primary endpoint revised
- Enrollment target: estimated 200 to confirmed 188
- Secondary endpoints expanded, about 18 words
- Study description expanded, about 2 words
- Study title expanded, about 2 words
Show 10 earlier versionsHide 10 earlier versions
- Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
- Primary and study completion dates: Jun 2026 to Nov 2026
- Minor Study sites: 42 to 47v11
- Minor Study sites revised (42)v9
- Minor Study sites: 34 to 42v8
- Minor Study sites: 31 to 34v7
- Minor Study sites: 25 to 31v6
- Minor Study sites: 18 to 25v5
- Minor Study sites: 1 to 18v4
- Minor Start date changed from estimate of Nov 2020 to Oct 26, 2020v3
- Minor Start date: Oct 2020 to Nov 2020v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies
Timeframe: During 42 months of follow-up
Secondary (3)
Area under the time-versus concentration curve (AUC) of C-peptide after a 4-hour (4h) mixed-meal tolerance test (MMTT)
Insulin use (daily average insulin dose in U/kg/day)
HbA1c
Arms and interventions
Teplizumab
Participants who received teplizumab in the PROTECT study
Placebo
Participants who received placebo in the PROTECT study
Biologicals: Teplizumab
Other: Placebo
Sites
47 sites in 8 countries
United States 25, France 7, Germany 5, Poland 4, Belgium 2, Canada 2, Czechia 1, United Kingdom 1